Key result
Fontan conversion shows no survival benefit over heart transplantation in patients with failing Fontan.
Why the study?
Surgical outcomes of Fontan takedown, Fontan conversion, and heart transplantation for failing Fontan patients were not well reported at a multicenter European level.
Do surgical outcomes differ between Fontan takedown, Fontan conversion, and heart transplantation in patients with failing Fontan?
Cohort (n=225)
Yes
Do surgical outcomes differ between Fontan takedown, Fontan conversion, and heart transplantation in patients with failing Fontan?
In patients with failing Fontan, Fontan conversion and heart transplantation offer similar survival outcomes, whereas Fontan takedown is associated with high early mortality.
Answers are grounded in this paper and cite their sources.
Multicenter outcomes for failing Fontan surgery inform risk counseling; leaves open optimal timing, patient selection, and comparative effectiveness.
OBJECTIVE: The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX. METHODS: A retrospective international study was conducted by the European Congenital Heart Surgeons Association among 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%). RESULTS: The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0-23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atriopulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04). CONCLUSIONS: Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.
No takes yet. Share an insight, caveat, or question.
Melle et al. (2016) conducted a cohort in Failing Fontan (n=225). Fontan conversion vs. Heart transplantation (HTX) was evaluated on Combined end point of all-cause mortality and (re-)HTX (p=0.13). Fontan conversion and heart transplantation showed no significant difference in survival for patients with failing Fontan.
Synapse has enriched 10 related papers. Consider them for comparative context: